What question did this study set out to answer?

This study aims to evaluate the efficacy of neoadjuvant ipilimumab-nivolumab-relatlimab therapy in patients with high-risk resectable melanoma.

A phase II study of neoadjuvant ipilimumab-nivolumab-relatlimab (INR) combination immunotherapy in high-risk resectable melanoma.

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates neoadjuvant immunotherapy effects on pathologic responses in high-risk melanoma, indicating significant clinical activity.

This study aims to evaluate the efficacy of neoadjuvant ipilimumab-nivolumab-relatlimab therapy in patients with high-risk resectable melanoma.
Phase II trial enrolling 20 patients with resectable AJCC8 stages IIIB-D melanoma.
Patients received ipilimumab 1 mg/kg and nivolumab-relatlimab 480/160 mg every 4 weeks followed by surgery.
Pathologic responses, recurrence-free survival, overall survival, and safety were evaluated.
Among 16 patients who had surgery, 63% achieved a complete path response (pCR; 95% CI, 38.64 – 81.52).
The major pathologic response (MPR) rate was 69% (11/16; 95% CI, 44.40 – 85.84).
No patients experienced recurrence after surgery during a median follow-up of 9.8 months.

Tarhini et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial evaluates neoadjuvant immunotherapy effects on pathologic responses in high-risk melanoma, indicating significant clinical activity.